Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $48.00

Apellis Pharmaceuticals (NASDAQ:APLS) had its price target boosted by HC Wainwright from $45.00 to $48.00 in a report published on Wednesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ Q1 2026 earnings at ($0.62) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.60) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.19) EPS, FY2027 earnings at ($2.02) EPS, FY2028 earnings at ($0.89) EPS, FY2029 earnings at $0.89 EPS and FY2030 earnings at $1.97 EPS.

Several other equities analysts have also recently issued reports on the company. Barclays began coverage on Apellis Pharmaceuticals in a research report on Wednesday, January 28th. They issued an “equal weight” rating and a $24.00 price target on the stock. Citigroup dropped their target price on Apellis Pharmaceuticals from $52.00 to $45.00 and set a “buy” rating on the stock in a report on Friday, October 31st. The Goldman Sachs Group restated a “sell” rating and set a $19.00 price target on shares of Apellis Pharmaceuticals in a research note on Monday, January 12th. Stifel Nicolaus lowered their price objective on shares of Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, December 19th. Finally, TD Cowen dropped their price objective on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Friday, October 31st. Twelve investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $32.61.

Apellis Pharmaceuticals Stock Performance

Shares of APLS opened at $20.96 on Wednesday. The company’s 50 day simple moving average is $23.00 and its 200-day simple moving average is $23.79. The firm has a market cap of $2.68 billion, a PE ratio of 161.24 and a beta of 0.26. Apellis Pharmaceuticals has a 12-month low of $16.10 and a 12-month high of $30.48. The company has a current ratio of 3.14, a quick ratio of 3.10 and a debt-to-equity ratio of 0.98.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.86. The firm had revenue of $199.91 million during the quarter, compared to analysts’ expectations of $199.28 million. Apellis Pharmaceuticals had a net margin of 2.23% and a return on equity of 8.20%. Apellis Pharmaceuticals’s quarterly revenue was down 5.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.29) EPS. As a group, equities analysts predict that Apellis Pharmaceuticals will post -1.7 EPS for the current year.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CAO James George Chopas sold 2,064 shares of the business’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $44,933.28. Following the sale, the chief accounting officer directly owned 49,805 shares in the company, valued at approximately $1,084,254.85. The trade was a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark Jeffrey Delong sold 3,371 shares of the company’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total value of $73,386.67. Following the completion of the sale, the insider directly owned 78,353 shares in the company, valued at $1,705,744.81. This trade represents a 4.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 120,537 shares of company stock worth $2,608,532. Corporate insiders own 6.50% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp grew its position in shares of Apellis Pharmaceuticals by 206.8% in the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock valued at $46,000 after purchasing an additional 1,373 shares during the last quarter. Osaic Holdings Inc. boosted its stake in shares of Apellis Pharmaceuticals by 141.2% during the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after acquiring an additional 1,570 shares during the last quarter. Allworth Financial LP raised its stake in Apellis Pharmaceuticals by 64.1% in the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after purchasing an additional 857 shares during the last quarter. Quantbot Technologies LP purchased a new position in Apellis Pharmaceuticals in the 3rd quarter valued at about $64,000. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Apellis Pharmaceuticals by 338.5% during the second quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock worth $94,000 after buying an additional 4,191 shares in the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Key Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright retains a “Buy” rating and a $48 price target, signaling continued analyst conviction in Apellis’ longer‑term upside. HC Wainwright Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) Stock
• Positive Sentiment: HC Wainwright published a long‑range forecast that includes a return to positive EPS by FY2030 (EPS ~$1.97), which underpins the firm’s $48 target and suggests expected recovery beyond the near term. HC Wainwright Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) Stock
• Neutral Sentiment: Apellis’ latest quarter delivered an EPS beat ($0.47 vs. expectations) but revenue was down ~6% year‑over‑year — a mixed fundamental print that reduces downside surprise risk but highlights demand pressure.
• Neutral Sentiment: Reported short‑interest data in recent filings appears anomalous (zero / NaN entries) and is not a reliable signal of investor positioning at this time.
• Negative Sentiment: HC Wainwright sharply lowered near‑term and multi‑year EPS forecasts (e.g., FY2026 cut to ~($2.19) from ($1.69); FY2027, FY2028 and several quarterly estimates were also reduced), increasing near‑term earnings uncertainty and pressuring the stock. HC Wainwright Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) Stock
• Negative Sentiment: Citigroup trimmed its price target to $44, signaling reduced upside in the nearer term and contributing to downward pressure. Citigroup Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $44.00
• Negative Sentiment: Wedbush and Royal Bank of Canada also lowered expectations, adding to the analyst‑driven sell pressure. Wedbush Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Royal Bank Of Canada Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.